















Abstract.	 A	 series	 of	 highly	 substituted	 tetrahydrofurans	 (THFs),	 decorated	 with	 modifiable	 2-aryl,	 3-
carboxy	and	4-amino	substituents,	has	been	prepared	 for	biological	evaluation	within	the	European	Lead	
Factory.	 Diastereoselective	 reductive	 amination	 of	 pre-functionalised	 4-oxofurans,	 readily	 prepared	 from	
cinnamate	esters	via	oxa-Michael/Dieckmann	annulation,	provided	the	requisite	THF	cores	on	gram	scale	
with	three	contiguous	stereocentres,	including	full	substitution	at	C-3.	In	a	second	series,	a	pyrrolidine	ring	
was	 fused	 to	 the	 same	 oxofuran	 scaffold	 via	 an	 intramolecular	 reductive	 amination,	 inverting	 the	






The	 search	 for	 new	 bioactive	 small	 molecules	 lies	 at	 the	 heart	 of	 modern	 drug	 discovery	
programmes.	 	 In	 addition,	 such	 molecules	 serve	 as	 useful	 probes	 for,	 and	 modulators	 of,	 the	







inspired	 a	 number	 of	 approaches	 to	 replicate	 the	 key	 structural	 features	 of	 these	 often	 densely	
functionalised	 small	bioactive	molecules,	 and	 this	has	been	aided	by	analysis	 and	 charting	of	 the	
chemical	 space	 populated	 by	 medicinally	 active	 natural	 products.[5,6]	 In	 attempting	 to	 define	
“natural	 product	 likeness”	 the	 analysis	 identified	 oxygen-containing	 heterocycles	 as	 a	 major	
contributor	to	chemical	space	for	drug	discovery.[5,6]	
Within	 the	 large	 family	 of	 oxygen	 heterocycle-containing	 natural	 products	 that	 occupy	
biologically	relevant	chemical	space,[5]	the	tetrahydrofuran	(THF)	ring	system	assumes	an	important	
place.	 It	 is	 found	 in	 myriad	 natural	 products,[7]	 biologically	 active	 small	 molecules[8]	 and	 FDA-
approved	drugs.[9]	 The	 significance	of	 the	THF	moiety	 in	medicinal	 chemistry	 continues	 to	 inspire	









the	heterocycle	backbone	(i.e.,	at	C-3	or	C-4).	 In	addition	to	serving	as	a	convenient	 template	 for	
library	 synthesis,	 the	biological	 activity	of	 amino-THFs	 is	well	 precedented	 (e.g.,	 compounds	1‒3,	

















treatment of schizophrenia [15]
3
43
                 3















Figure	 1).[15‒17]	 In	 the	 design	 of	 a	 lead-like	 scaffold[18]	 incorporating	 this	 structural	 feature	 that	
fulfilled	the	requirements	of	the	ELF,[14]	we	 identified	THF	4	as	our	principal	target	(Scheme	1).	 In	
addition	 to	 the	 key	 amino	group	at	C-4,	 a	 carboxylic	 acid	or	derived	 functionality	 (e.g.,	 amide	or	
hydroxymethyl)	 was	 proposed	 at	 C-3	 as	 a	 second	 major	 point	 for	 orthogonal	 diversification.	
Notably,	 despite	 the	 intense	 general	 interest	 in	 THF-based	 amino	 acids,[19]	 THFs	 containing	 an	
embedded	 β-amino	 acid	 (or	 derivative)	 of	 equivalent	 constitution	 to	 compound	 4	 remain	
underrepresented	 in	 the	 literature.[20]	 To	 complete	 our	 scaffold	 design,	 an	 aryl	 group	 was	




of	 prime	 importance	 to	 establish	 a	 synthetic	 pathway	 capable	 of	 controlling	 the	 relative	
stereochemistry	at	three	contiguous	centres	(C-2,	C-3,	C-4)	with	high	fidelity,	in	favour	of	one	of	the	
four	 possible	 diastereomers.	 To	 gain	 access	 to	 our	 primary	 target,	 we	 envisioned	 a	 reductive	
amination	 using	 4-oxofuran	 5,	 which	 itself	 could	 arise	 from	 a	 tandem	 oxa-Michael/Dieckmann	
condensation	 using	 readily	 available	 starting	 materials,	 namely	 glycolate	 6	 and	 cinnamate	 7	
(Scheme	1).	The	β-keto	ester	functionality	embedded	in	4-oxofuran	5	was	also	expected	to	endow	
flexibility	to	produce	C-3	fully-substituted	derivatives	via	alkylation,[23]	 including	introduction	of	an	

































The	oxa-Michael/Dieckmann	 annulation	 of	 the	 type	 shown	 in	 Scheme	1	 is	well	 established	using	
acrylate	esters	or	β-alkyl-acrylate	esters	as	Michael	acceptors,[24[	but	there	is	little	precedent	for	the	
use	of	 less	 electrophilic	 cinnamate	esters[25]	 in	 such	a	process	 to	provide	an	aryl	 group	at	C-2.[26]	
After	considerable	optimisation	(base/solvent/temperature/time/R	group	in	Scheme	2),	we	arrived	
at	 a	 practical	 procedure	 to	 obtain	 the	 required	 oxo-furans	 9	 and	 10	 on	 decagram	 scales	 in	
reasonable	yields	(Scheme	2).	Our	choice	to	prepare	the	meta-methoxy	derivative	10	was	based	on	
the	installation	of	an	activating/directing	group	to	enable	potential	late-stage	electrophilic	aromatic	











Installation	 of	 the	 requisite	 C-4-amino	 group	 was	 investigated	 via	 stepwise	 formation	 of	 a	 β-
enamino	ester	 and	 subsequent	 reduction	 (Scheme	2).	Our	 initial	 attempt	 to	prepare	an	enamine	






JH2-H3 = 10.2 Hz 
(all compounds)
  9: R = Me,  R1 = H       53% (20.5 g)
10: R = Me,  R1 = OMe  42% (21.2 g)
11: R = t-Bu, R1 = H       20% [+ 9: 14%]
(X-ray crystal 
 structure of 11) 12: R3 = H        100% (rt, 5.5 d)






















enamine	12	 due	 to	predominant	C-3‒C-4	bond	 cleavage	by	methanol-mediated	 retro-Dieckmann	
reaction	(Scheme	S1,	SI).	This	competing	side	reaction	was	completely	suppressed	by	switching	to	
the	 less	 nucleophilic	 trifluoroethanol	 as	 solvent,	 giving	 a	 quantitative	 yield	 of	 enamine	 12	 and,	
under	 similar	 conditions,	 a	 94%	 yield	 of	 benzhydryl-protected	 analogue	 13	 (Scheme	 2).	 These	
compounds	 were	 obtained	 in	 high	 purity	 after	 a	 simple	 aqueous	 work-up	 and	 were	 indefinitely	
stable	to	room	temperature	storage.	Under	analogous	conditions,	three	additional	enamines	were	
prepared	 from	β-ketoester	 9	 using	 functionalised	 amines,	 all	 in	 excellent	 yields	 (Scheme	 S2,	 SI).	
Despite	having	efficient	access	 to	enamines	12	and	 13,	we	were,	however,	unable	 to	affect	 their	
reduction	 to	 the	 corresponding	 β-amino	 esters	 14	 under	 standard	 protocols	 (Scheme	 2),[27]	
resulting	in	decomposition	and/or	complex	mixtures	that	did	not	contain	the	desired	products	(for	
specific	 conditions	attempted,	 see	Table	S1,	 SI).	We	 thus	 turned	our	attention	 to	alkylation	of	β-
ketoesters	9	and	10	with	the	aim	of	preparing	C-3	fully-substituted	derivatives.	Although	this	would	
increase	 the	 steric	 encumbrance	 of	 the	 ketone,	 we	 envisioned	 that	 removing	 (enamine)	
conjugation	with	 the	 ester	would	 increase	 the	 reactivity	 of	 a	 derived	 imine	 towards	 protonation	
and	 reduction.	 Accordingly,	 3-methyl	 derivatives	 15	 and	 16	were	 prepared	 by	 treatment	 of	 β-
ketoester	9	 and	10	 with	 iodomethane	 in	 the	 presence	 of	 potassium	 carbonate	 (Scheme	 3).	 This	































15: R1 = H       69%[a]  [+ epi-15: 5%[a]]
16: R1 = OMe  64%[a]  [+ epi-16: 7%[b]]
CH(Ph)2NH2 (5 equiv) 
NaBH3CN, AcOH 
3 Å MS, MeOH, 60 °C, 17 h
17: R1 = H       48%[a,c] (3.8 g)
18: R1 = OMe  55%[a]   (1.5 g)
DDQ, 4 Å MS, benzene 
60 °C, 1-2 h
then 1 M HClaq, MeOH
rt, 10-30 min
19: R1 = H       83%



































good‒excellent	 yields	 of	 amides	 29‒31,	 despite	 the	 sterically	 encumbered	 nature	 of	 the	 acid.	
Separately,	alcohol	32	was	produced	(79%	yield)	by	reduction	of	ester	25	with	lithium	borohydride.	



















130 °C, 7 d
LiOH (10 equiv)
dioxane/H2O (4:1)






















methylation	 (K2CO3,	THF,	Scheme	6).	Although	heating	was	 required	 to	ensure	adequate	 reaction	
rates,	the	desired	products	37	and	38	were	formed	in	good	yields	and	excellent	diastereoselectivity	
(dr	 =	 ≥20:1	 after	 work-up),	 with	 the	 same	 stereochemical	 preference	 as	 observed	 in	 the	
methylation,	as	confirmed	through	X-ray	crystal	structures	of	downstream	derivatives	47	(Scheme	
6)	 and	 58	 (Scheme	 8).	 Using	 these	 terminal	 alkenes	 (37	 and	 38),	 a	 one-pot	 tandem	
ozonolysis/double	reductive	amination	procedure	was	developed	using	4-methoxybenzylamine	and	
sodium	 cyanoborohydride	 as	 reductant,[33]	 enabling	 the	 preparation	 of	 multigram	 quantities	 of	
pyrrolidino-THFs	 39	 and	 40	 in	 rapid	 fashion	 with	 modest	 yields	 (55	 and	 59%).	 In	 this	 case,	 the	
requirement	for	a	cis-fused	pyrrolidine	ring	in	the	5,5-bicycle	overrides	the	previous	stereochemical	
preference	for	hydride	delivery	trans	to	the	ester	in	the	intermolecular	case	(see	amine	products	17	








25: R1 = H       98%






100 °C, 37-50 h
27: R1 = H       85%











29: R1 = H       91%
















33: R1 = H       89%































  (27 only)
(amine = BnNH2)
9	










THF	 scaffolds,	 allowing	 further	manipulations	 to	 be	 performed	 in	 a	 similar	manner	 to	 previously	
described	as	outlined	in	Schemes	6	and	7.	The	ester	was	hydrolysed	to	zwitterionic	amino	acids	42	
and	43,	which	were	isolated	in	88%	and	74%	yields,	respectively,	after	precipitation	from	water	at	
pH	 5	 (Scheme	 6).	 Alternatively,	 exchange	 of	 the	 para-methoxybenzyl	 (PMB)	 group	with	 the	 Boc	
group[35]	 using	 1-chloroethyl	 chloroformate,[36]	 allowed	preparation	of	 Boc-protected	 amino	 acids	
46	and	47	(Scheme	6),	which	were	readily	amenable	to	amide	coupling	reactions	or	reduction	with	
lithium	 borohydride	 (Scheme	 7).	 The	 obtained	 amides	 48‒50	 and	 alcohol	 51	 were	 cleanly	
deprotected	with	 TFA	 to	 give	 an	 additional	 set	 of	 scaffolds	52‒55	with	 an	 unmasked	 pyrrolidine	
nitrogen	(Scheme	7).	
K2CO3, THF
60 °C, 15-23 h
37: R1 = H       74%[a]
38: R1 = OMe  80%[a]
O3, CH2Cl2, -78 °C
5-15 min
then NaBH3CN (4 equiv)
PMBNH2 (1.1 equiv)
AcOH, MeOH, 
-78 °C-rt, 24 h
39: R1 = H       55%   (2.6 g)
                    or 46% (14.3 g)
40: R1 = OMe  59%   (1.7 g)
LiOH (10 equiv)
dioxane/H2O (4:1)
100 °C, 45-65 h
42: R1 = H       88%








100 °C, 22-25 h
1-chloroethyl chloroformate
CH2Cl2, 0 °C, 3-4 h
then MeOH, 65 °C, 30-45 min
then Boc2O, NEt3, CH2Cl2
0 °C-rt, 2-3 h
44: R1 = H       87%
45: R1 = OMe  80%
46: R1 = H       91%



































The	 relative	orientation	of	 the	 three	 stereocentres	 in	 the	monocyclic	 and	bicyclic	 THF	 scaffolds	
was	confirmed	through	X-ray	crystal	structures	of	derivatives	56‒58,	prepared	via	N-sulfonylation,	
aryl	 bromination	 and	N-acylation,	 respectively	 (Scheme	 8).	 Notably,	 the	 cis-relationship	 between	
the	amino	group	and	 the	amide	 in	 the	monocyclic	 THF	 system	 (i.e.,	56	 and	57)	 compared	 to	 the	
trans-arrangement	 in	 the	 bicyclic	 scaffold	 (58),	 allows	 the	 occupation	 of	 distinct	 chemical	 space	
from	the	N-substituent	between	the	two	systems.	Further,	the	facile,	regioselective	bromination[37]	
of	THF	30	 demonstrates	 the	potential	of	 the	methoxy	group	 to	enable	 chemoselective	 late-stage	
functionalisation	of	 the	 aryl	 ring,	 as	mentioned	earlier.	 This	 halogen	 could	potentially	 be	used	 in	




0 °C-rt, 24-34 h
50: 96%48: R1 = H       93%
49: R1 = OMe  85%
(amine = 
  pyrrolidine)

















52: R1 = H       86%







































AlogP	was	 formulated	using	 the	computational	model	LLAMA[21]	 (Figure	2;	physical	properties	 for	
each	compound	are	fully	documented	in	Table	S2,	SI).	Each	of	these	core	scaffolds	retains	either	a	
nucleophilic	amino	group	or	a	carboxylic	acid	functionality,	offering	potential	to	create	compound	
libraries	 through	 further	 derivatisation.	As	 shown	 in	 Figure	 2,	 all	 examples	 fall	within	 or	 close	 to	
lead-like	 territory[18]	 (molecular	 weight	 <350,	 AlogP	 <3),	 enabling	 significant	 flexibility	 for	
derivatisation	within	Lipinski	space	(molecular	weight	<500,	AlogP	<5).	A	balanced	pharmacokinetic	
profile	is	predicted	by	an	average	AlogP	of	1.7	and	topological	polar	surface	area	(TPSA)	of	59.3	Å2	













































Figure	 2.	 Chemical	 space	 distribution	 of	 the	 prepared	 scaffolds	 relative	 to	molecular	 weight	 and	 AlogP,	
generated	using	LLAMA.[21]	Data	points	are	labelled	with	the	corresponding	compound	numbers.		
	
The	principal	moments	of	 inertia	 (PMI)[40]	 plot	of	 the	12	 compounds	 (Figure	3,	 generated	using	













82)	 was	 prepared	 and	 fully	 characterised	 (Figure	 4;	 full	 details	 are	 given	 in	 the	 SI).	 Standard	
transformations	 were	 utilised	 including	 N-acylation,	 N-reductive	 alkylation,	 N-sulfonylation	 and	
carboxylic	 acid-amide	 couplings.	 Outside	 of	 this	 compound	 set	 (Figure	 4),	 an	 additional	 1948	
compounds	 were	 prepared	 and	 submitted	 to	 the	 Joint	 European	 Compound	 Library	 (JECL),[46]	
consisting	of	923	derivatives	of	4	with	an	average	molecular	weight	of	403	and	an	average	clogP	of	
2.0	and	1025	derivatives	of	8	with	an	average	molecular	weight	of	448	and	an	average	clogP	of	2.5	








A	 series	 of	 highly	 substituted	 THFs	 and	 pyrrolidino-THFs	 embedded	 with	 modifiable	 2-aryl,	 3-
carboxy	and	4-amino	functionalities	has	been	prepared.	Divergent	synthetic	routes	were	developed	
From carboxylic acids 23 and 24 (43-59% yield):




















































































From carboxylic acid 42 (20-73% yield):





















































































































to	 access	 the	 desired	mono-	 and	 bicyclic	 scaffolds	 via	 a	 common	 4-oxofuran	 intermediate,	 from	
which	 inter-	 and	 intramolecular	 reductive	 aminations,	 respectively,	 enabled	 diastereoselective	
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